Details for New Drug Application (NDA): 206030
✉ Email this page to a colleague
NDA 206030 describes CARNEXIV, which is a drug marketed by Lundbeck Pharms Llc and is included in one NDA. There are seven patents protecting this drug. Additional details are available on the CARNEXIV profile page.
The generic ingredient in CARNEXIV is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.
The generic ingredient in CARNEXIV is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.
Summary for 206030
| Tradename: | CARNEXIV |
| Applicant: | Lundbeck Pharms Llc |
| Ingredient: | carbamazepine |
| Patents: | 7 |
Medical Subject Heading (MeSH) Categories for 206030
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 200MG/20ML (10MG/ML) | ||||
| Approval Date: | Oct 7, 2016 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jan 31, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 13, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 13, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
